BridgeBio Pharma (NASDAQ:BBIO) Stock: Insider Maricel Apuli Sells 2,000 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CAO Maricel Apuli sold 2,000 shares of the stock in a transaction on Friday, October 30th. The shares were sold at an average price of $72.85, for a total value of $145,700.00. Following the transaction, the chief accounting officer directly owned 120,687 shares of the company’s stock, valued at approximately $8,792,047.95. The trade was a 1.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Price Performance

Shares of BBIO traded down $0.97 during midday trading on Tuesday, reaching $74.03. The stock had a trading volume of 2,478,769 shares, compared to its average volume of 2,901,362. BridgeBio Pharma, Inc. has a 52 week low of $60.22 and a 52 week high of $93.42. The firm’s 50 day moving average price is $70.14 and its 200-day moving average price is $72.82. The company has a market capitalization of $14.47 billion, a P/E ratio of -24.35 and a beta of 0.97.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Thursday, October 29th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.12. The firm had revenue of $353.17 million for the quarter, compared to the consensus estimate of $293.47 million. The company’s quarterly revenue was up 192.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.95) EPS. On average, equities analysts forecast that BridgeBio Pharma, Inc. will post -2.65 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BBIO. Jupiter Topco LLC purchased a new stake in BridgeBio Pharma in the 2nd quarter worth approximately $1,050,762,000. Janus Henderson Group PLC grew its holdings in shares of BridgeBio Pharma by 19.8% during the 1st quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock valued at $978,608,000 after acquiring an additional 2,178,556 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of BridgeBio Pharma during the 2nd quarter valued at $145,663,000. Primecap Management Co. CA purchased a new position in shares of BridgeBio Pharma during the 2nd quarter valued at $75,670,000. Finally, Squarepoint Ops LLC increased its stake in shares of BridgeBio Pharma by 114.2% in the second quarter. Squarepoint Ops LLC now owns 1,191,732 shares of the company’s stock worth $88,760,000 after acquiring an additional 635,408 shares during the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on BBIO. TD Cowen dropped their target price on shares of BridgeBio Pharma from $110.00 to $100.00 and set a “buy” rating on the stock in a report on Friday. Wells Fargo & Company raised their target price on shares of BridgeBio Pharma from $98.00 to $102.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Citigroup decreased their price target on shares of BridgeBio Pharma from $94.00 to $91.00 and set a “neutral” rating on the stock in a research report on Monday, October 19th. UBS Group reaffirmed a “buy” rating on shares of BridgeBio Pharma in a report on Friday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of BridgeBio Pharma in a research report on Monday, October 5th. Nineteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, BridgeBio Pharma has a consensus rating of “Moderate Buy” and an average price target of $104.26.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes.

BridgeBio’s portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms.